The FDA’s ODAC voted that data support the use of minimal residual disease as an end point to support accelerated approval of treatments in multiple myeloma.
By a unanimous 12-0 vote, the U.S. FDA’s Oncologic Drugs Advisory Committee concluded that new evidence support the use of minimal residual disease (MRD) as an accelerated approval endpoint in multiple myeloma (MM) clinical trials.